ScholarIQanswers from OpenAlex
Acta Pharmacologica Sinica
JournalCitation impact & published research
Acta Pharmacologica Sinica is a journal indexed in ScholarIQ from OpenAlex.
How many works does Acta Pharmacologica Sinica have?
ScholarIQindexed works
Acta Pharmacologica Sinica has 4,718 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Acta Pharmacologica Sinica have?
ScholarIQcitation count
Acta Pharmacologica Sinica has 174,939 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Acta Pharmacologica Sinica?
ScholarIQh-index
Acta Pharmacologica Sinica has an h-index of 145 in OpenAlex.
What is the article processing charge of Acta Pharmacologica Sinica?
ScholarIQarticle processing charge
Acta Pharmacologica Sinica lists an article processing charge of 3,990 USD in OpenAlex.
What is the OpenAlex record for Acta Pharmacologica Sinica?
ScholarIQopenalex
The OpenAlex for Acta Pharmacologica Sinica is on the source record.
What are the most-cited papers on Acta Pharmacologica Sinica?
ScholarIQmost cited works
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients
Hai-xia Su, Sheng Yao, Wen-feng Zhao, Min-jun Li, Jia Liu, Wei-juan Shang, Hang Xie, Chang-Qiang Ke, Hang-chen Hu, Mei-na Gao, Kun-qian Yu, Hong Liu, Jing-shan Shen, Wei Tang, Leike Zhang, Gengfu Xiao, Li Ni, Dao Wen Wang, Jianping Zuo, Hua-liang Jiang, Fang Bai, Yan Wu, Ye Yang, Ye-chun Xu
Artemisinin analogue SM934 ameliorates DSS-induced mouse ulcerative colitis via suppressing neutrophils and macrophages
Yuxi Yan, Meijuan Shao, Qing Qi, Yansheng Xu, Xiaoqian Yang, Fenghua Zhu, Shijun He, Pei‐Lan He, Chunlan Feng, Yanwei Wu, Heng Li, Wei Tang, Jianping Zuo
Natural dietary anti-cancer chemopreventive compounds: redox-mediated differential signaling mechanisms in cytoprotection of normal cells versus cytotoxicity in tumor cells
Sujit Nair, Wenge Li, Ah‐Ng Tony Kong
Toll-like receptors: potential targets for lupus treatment
Yanwei Wu, Wei Tang, Jianping Zuo
PI3K isoform-selective inhibitors: next-generation targeted cancer therapies
Xiang Wang, Jian Ding, Linghua Meng